147 related articles for article (PubMed ID: 11350909)
1. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
[TBL] [Abstract][Full Text] [Related]
2. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
3. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
van Acker FA; van Acker SA; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2000 Apr; 6(4):1337-41. PubMed ID: 10778960
[TBL] [Abstract][Full Text] [Related]
4. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
[TBL] [Abstract][Full Text] [Related]
6. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
7. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
[TBL] [Abstract][Full Text] [Related]
9. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Apr; 51(4):306-10. PubMed ID: 12721758
[TBL] [Abstract][Full Text] [Related]
10. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
11. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
van Acker SA; Kramer K; Grimbergen JA; van den Berg DJ; van der Vijgh WJ; Bast A
Br J Pharmacol; 1995 Aug; 115(7):1260-4. PubMed ID: 7582554
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
[TBL] [Abstract][Full Text] [Related]
13. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
[TBL] [Abstract][Full Text] [Related]
14. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
15. Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
Jacobs H; Peters R; den Hartog GJ; van der Vijgh WJ; Bast A; Haenen GR
Drug Metab Dispos; 2011 May; 39(5):750-6. PubMed ID: 21266594
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity.
Khan M; Shobha JC; Mohan IK; Naidu MU; Sundaram C; Singh S; Kuppusamy P; Kutala VK
Phytother Res; 2005 Dec; 19(12):1030-7. PubMed ID: 16372368
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin).
Ryu JS; Lee HS; Hong YS; Lee JJ; Sohn UD; Kim TY
Cancer Chemother Pharmacol; 2006 Jun; 57(6):811-8. PubMed ID: 16175393
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
